Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 289

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial

Park, Seung-Jung, Ahn, Jung-Min, Kang, Do-Yoon, Yun, Sung-Cheol, Ahn, Young-Keun, Kim, Won-Jang, Nam, Chang-Wook, Jeong, Jin-Ok, Chae, In-Ho, Shiomi, Hiroki, Kao, Hsien-Li, Hahn, Joo-Yong, Her, Sung-Ho, Lee, Bong-Ki, Ahn, Tae Hoon, Chang, Ki-Yuk, Chae, Jei Keon, Smyth, David, Mintz, Gary S, Stone, Gregg W, Park, Duk-Woo, Park, Seung-Jung, Ahn, Jung-Min, Kang, Do-Yoon, Yun, Sung-Cheol, Ahn, Young-Keun, Kim, Won-Jang, Nam, Chang-Wook Nam, Jeong, Jin-Ok, Chae, In-Ho, Shiomi, Hiroki Shiomi, Kao, Hsien-Li, Hahn, Joo-Yong, Her, Sung-Ho, Lee, Bong-Ki, Ahn, Tae Hoon, Chang, Ki-Yuk, Chae, Jei-Keon, Smyth, David, Mintz, Gary, Stone, Gregg, Park, Duk-Woo · 2024 · The Lancet

Abstract

BACKGROUND Acute coronary syndrome and sudden cardiac death are often caused by rupture and thrombosis of lipid-rich atherosclerotic coronary plaques (known as vulnerable plaques), many of which are non-flow-limiting. The safety and effectiveness of focal preventive therapy with percutaneous coronary intervention of vulnerable plaques in reducing adverse cardiac events are unknown. We aimed to assess whether preventive percutaneous coronary intervention of non-flow-limiting vulnerable plaques improves clinical outcomes compared with optimal medical therapy alone. METHODS PREVENT was a multicentre, open-label, randomised controlled trial done at 15 research hospitals in four countries (South Korea, Japan, Taiwan, and New Zealand). Patients aged 18 years or older with non-flow-limiting (fractional flow reserve >0·80) vulnerable coronary plaques identified by intracoronary imaging were randomly assigned (1:1) to either percutaneous coronary intervention plus optimal medical therapy or optimal medical therapy alone, in block sizes of 4 or 6, stratified by diabetes status and the performance of percutaneous coronary intervention in a non-study target vessel. Follow-up continued annually in all enrolled patients until the last enrolled patient reached 2 years after randomisation. The primary outcome was a composite of death from cardiac causes, target-vessel myocardial infarction, ischaemia-driven target-vessel revascularisation, or hospitalisation for unstable or progressive angina, assessed in the intention-to-treat population at 2 years. Time-to-first-event estimates were calculated with the Kaplan-Meier method and were compared with the log-rank test. This report is the principal analysis from the trial and includes all long-term analysed data. The trial is registered at ClinicalTrials.gov, NCT02316886, and is complete. FINDINGS Between Sept 23, 2015, and Sept 29, 2021, 5627 patients were screened for eligibility, 1606 of whom were enrolled and randomly assigned to percutaneous coronary intervention (n=803) or optimal medical therapy alone (n=803). 1177 (73%) patients were men and 429 (27%) were women. 2-year follow-up for the primary outcome assessment was completed in 1556 (97%) patients (percutaneous coronary intervention group n=780; optimal medical therapy group n=776). At 2 years, the primary outcome occurred in three (0·4%) patients in the percutaneous coronary intervention group and in 27 (3·4%) patients in the medical therapy group (absolute difference -3·0 percentage points [95% CI -4·4 to -1·8]; p=0·0003). The effect of preventive percutaneous coronary intervention was directionally consistent for each component of the primary composite outcome. Serious clinical or adverse events did not differ between the percutaneous coronary intervention group and the medical therapy group: at 2 years, four (0·5%) versus ten (1·3%) patients died (absolute difference -0·8 percentage points [95% CI -1·7 to 0·2]) and nine (1·1%) versus 13 (1·7%) patients had myocardial infarction (absolute difference -0·5 percentage points [-1·7 to 0·6]). INTERPRETATION In patients with non-flow-limiting vulnerable coronary plaques, preventive percutaneous coronary intervention reduced major adverse cardiac events arising from high-risk vulnerable plaques, compared with optimal medical therapy alone. Given that PREVENT is the first large trial to show the potential effect of the focal treatment for vulnerable plaques, these findings support consideration to expand indications for percutaneous coronary intervention to include non-flow-limiting, high-risk vulnerable plaques. FUNDING The CardioVascular Research Foundation, Abbott, Yuhan Corp, CAH-Cordis, Philips, and Infraredx, a Nipro company.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(24)00413-6

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Metadata

Authors
Park, S.-J., Ahn, J.-M., Kang, D.-Y., Yun, S.-C., Ahn, Y.-K., Kim, W.-J., Nam, C.-W., Jeong, J.-O., Chae, I.-H., Shiomi, H., Kao, H.-L., Hahn, J.-Y., Her, S.-H., Lee, B.-K., Ahn, T. H., Chang, K.-Y., Chae, J. K., Smyth, D., Mintz, G. S., Stone, G. W., Park, D.-W., Park, S.-J., Ahn, J.-M., Kang, D.-Y., Yun, S.-C., Ahn, Y.-K., Kim, W.-J., Nam, C.-W. N., Jeong, J.-O., Chae, I.-H., Shiomi, H. S., Kao, H.-L., Hahn, J.-Y., Her, S.-H., Lee, B.-K., Ahn, T. H., Chang, K.-Y., Chae, J.-K., Smyth, D., Mintz, G., Stone, G., & Park, D.-W.
Venue
The Lancet
Publisher
Elsevier BV
Published
2024-05
Volume
403
Issue
10438
Pages
1753-1765
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4394579663
Cited by
289
References
24
FWCI
110.55
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(24)00413-6
The paper
Park, S.-J., Ahn, J.-M., Kang, D.-Y., Yun, S.-C., Ahn, Y.-K., Kim, W.-J., Nam, C.-W., Jeong, J.-O., Chae, I.-H., Shiomi, H., Kao, H.-L., Hahn, J.-Y., Her, S.-H., Lee, B.-K., Ahn, T. H., Chang, K.-Y., Chae, J. K., Smyth, D., Mintz, G. S., . . . Park, D.-W. (2024). Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(24)00413-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.